Is stem cell therapy for Parkinson's Disease FDA-approved?
No regenerative medicine therapy is FDA-approved to treat Parkinson's disease. A Phase 1 or Phase 2 study, RMAT designation, IND, facility registration or trial listing is not marketing approval.
How stem cells are studied for Parkinson's Disease
Parkinson's disease involves progressive loss and dysfunction of dopaminergic and other neural systems. Research includes pluripotent-stem-cell-derived dopaminergic progenitors intended for intracerebral transplantation, as well as unrelated MSC or exosome proposals. These products, routes and objectives are not interchangeable, and replacing cells does not automatically control the wider disease process.
Am I a candidate? → · Parkinson's Disease: full overview → · Parkinson's Disease cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Parkinson's Disease: cell-therapy evidence and registered trials
- How much does stem cell therapy for Parkinson's Disease cost? (2026)
- Parkinson's Disease stem cell therapy — your questions answered (2026)
- Parkinson's Disease: cell-therapy evidence by therapy class
- MSC vs exosomes for Parkinson's Disease: what the registries show